Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Non-segmental Vitiligo
NCT05676333Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in nonsegmental vitiligo (NSV), sponsored by Ghent University Hospital. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT05676333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676333.